VBI: Interim Phase 2 Data on VBI-2601 (BRII-179) and BRII-835 for Hepatitis B

 

• BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed
• Initial data suggest VBI-2601 (BRII-179) and BRII-835 combination induced meaningfully stronger anti-hepatitis B surface antigen (HBsAg)-specific T-cell and antibody responses compared to BRII-835 alone
• Data to be featured in oral presentation, given by Dr. Man Fung Yuen, M.D., Ph.D., D.Sc., at the 32^nd Conference of the Asian Pacific Association for the Study of the Liver (APASL) 2023 in Taipei, Taiwan on February 18, 2023

https://www.biospace.com/article/releases/vbi-vaccines-announces-presentation-of-interim-phase-2-data-evaluating-combination-of-vbi-2601-brii-179-and-brii-835-for-the-treatment-of-chronic-hepatitis-b-/